Thanks for those e-mails. The pleasure I can from reading boring old PACE correspondence makes me realise I'm a true nerd. Is there any demand for a full-time PACE historian?
I have rather a high number of emails .....! Then I was better at filing them. It's good to know the old brain cells and memory are still working!
This is a corker of an email!
Sent: Saturday, May 15, 2004 7:01 PM
Subject: [CO-CURE] ACT: The PACE and FINE trials: correcting some misunderstandings
"From Dr. Peter D. White:
The PACE and FINE trials: correcting some misunderstandings
The UK national newspaper, The Independent, published an article on May
11th, which included a number of misunderstandings about these two
scientific trials of treatments of CFS/ME. The Independent has today
published letters of correction from us as the Principal Investigators in
the trials, and from the MRC as the main funder of the trials. We
understand that the journalist drew strongly on misunderstandings that were
first published on this web-site. We believe it will be helpful for those
who haven't had the opportunity to read the letters in the Independent to
have access to them through Co-Cure.
<http://argument.independent.co.uk/letters/story.jsp?story=521407>
There were three main misunderstandings carried by this web-site:
1. Sufferers of the neurological disease ME/CFS ICD-10 G93.3 will not be
able to enter the trial and will be excluded because the Oxford criteria
specifically states that those with an organic brain disease such as ME/CFS
must be so excluded.
The actual position: The criteria that we will use to include patients with
CFS/ME do not exclude ME. The trial is designed to answer the question as
to whether these treatments are helpful or unhelpful or even harmful in
people with different definitions of CFS/ME, including the Fukuda criteria
and the London criteria for ME.
2. Designed and set up by psychiatrists, the psychiatric PACE clinical
trial will use psychosocial management regimes and treatments that have
comprehensively been shown to be at best ineffective and in many instances
have made sufferers of the neurological disease ME/CFS ICD-10 G93.3
dramatically worse.
The actual position: The PACE and FINE trial research teams, which have
designed and set up the trials, include 6 physicians (5 specialists in
infectious disease, and one immunologist), 5 nurses, 3 statisticians, 3
health economists, 3 psychologists, 2 general practitioners, 2 counsellors,
1 physiotherapist, 1 occupational therapist, 1 cognitive behaviour
therapist, two representatives of Action for M.E., and only 5 psychiatrists.
The trials will be testing supplements to usual specialist medical care:
pacing, pragmatic rehabilitation, and graded exercise therapy (none of
which could be described as psychiatric or psychosocial) and cognitive
behaviour therapy. These treatments will be given by nurses,
physiotherapists, occupational therapists, and psychotherapists; not
psychiatrists.
Several systematic reviews have shown that these treatments show most
promise for CFS/ME and there is no evidence that they are harmful if
carried out with the help of appropriately trained and qualified
therapists. It is highly likely that reports of harm, especially after
graded exercise therapy, result from poor understanding of CFS/ME and the
misapplication of approaches by inexperienced or untrained therapists. We
will however look for evidence of harm as well as improvement in these
trials, and both trials will be overseen by two independent committees to
ensure that no treatment is intrinsically harmful to participants.
3. It is wrong that the psychiatrists carrying out this research are
themselves employed to provide the therapies being studied at the newly
operational ME/CFS centres. It is unethical for people with proven
commercial interests in these studies to be designing and running this
£2.5m trial, given the proven evidence of their commercial interest in the
desired outcome.
The actual position: None of the psychiatrists are employed to provide any
of these therapies. No researcher will make any personal financial gain
from these trials.
Conclusion
The most important point we wish to make is that these two trials will
answer important questions about what current treatments are most helpful
to people with CFS/ME, and will include treatments that will be available
to the most severely affected.
We will not post any further Co-Cure web-site correspondence on this
matter.. The trial teams will be developing websites over the next few
months to provide accurate and up to date information about the trials. We
hope these will be a useful source of information for the CFS/ME community,
including those recruited to the trial.
Dr Peter White
Professor Michael Sharpe
Professor Trudie Chalder
Dr Alison Wearden
Principal Investigators for the PACE and FINE trials